Antibe Therapeutics Inc. (T.ATE) hit a new 52-week high of 73 cents Wednesday. Antibe announced the completion of the pharmacokinetic/pharmacodynamic study of otenaproxesul’s faster-absorbing formulation for acute pain. The study was designed to confirm ...